期刊文献+

肿瘤标志物联合检测在胃癌诊断及预后评估中的价值 被引量:48

Evaluation of serum tumor markers in diagnosis and monitoring prognosis of patients with gastric cancer
原文传递
导出
摘要 目的 探讨血清癌胚抗原(CEA)、唾液酸化岩藻戊糖(CA199)、胃肠道癌抗原(CA242)、甲胎蛋白(AFP)、胃癌及卵巢癌抗原(CA724)对胃癌的诊断及患者的预后评价价值.方法 回顾性分析诊断为胃癌并接受手术治疗的108例患者,应用电化学发光和酶联免疫法检测外周血清CEA、CA199、CA242、CA724、AFP水平.以108例胃癌患者标本绘制5种标志物受试者工作曲线(ROC);Kaplan-Meier 法分析胃癌患者生存时间;Cox比例风险模型分析影响胃癌患者预后的因素.结果 CEA、CA199、CA242、CA724诊断胃癌的ROC曲线AUC分别为0.735,0.714,0.598,0.576.检测敏感度、特异度、约登指数分别为40.2%、97.7%、0.379;43.0%、91.3%、0.343;35.2%、94.8%、0.300;31.3%、95.3%、0.266.CEA、CA199、CA242、CA724联合诊断胃癌的敏感度、特异度、约登指数分别为76.8%、82.3%、0.585.CEA、CA724与淋巴结转移相关(均P< 0.05);血清CEA、CA199、CA242水平与脉栓、远处转移相关及腹腔积液形成有关(均P<0.05).肿块型和导管型患者血清AFP的水平高于浸润性和溃疡型患者(P<0.05).肿瘤大小与CEA、AFP、CA724有关.Cox逐步回归分析显示,影响患者3年生存期的因素有术前CEA浓度>3 μg/ml(P=0.000)、淋巴结转移(P=0.002).随访59例患者中34例死亡,术前CEA阴性与阳性患者中位生存期分别为18.1、10.9个月(P<0.005).结论 联合检测血清CEA、CA199、CA242、CA724可提高胃癌检出率,同时对预测胃癌患者的复发、转移;术前CEA为胃癌患者唯一不良预后指标. Objective To investigate the serum CEA, CA199, CA242, CA724, AFP levels as tumor markers for diagnosis and prognosis of gastric cancer. Methods The serum concentrations of CEA, CA199, CA724, AFP were detected in 108 patients with gastric cancer by ECLIA (electrochemiluminescence immunoassay) method. CA242 by ELISA method. The survival analysis was performed by the Kaplan-Meier method, Cox" s proportional hazards model was used for multivariate analysis of prognosis. Results Using healthy subjects group as control, the ROC-AUC of CEA, CA199, CA242, CA724 were 0.735, 0.714, 0.598, 0.576. The sensitivity, specificity and Youden index were 40.2 %, 97.7 %, 0.379; 43.0 %, 91.3 %, 0.343; 35.2 %, 94.8 %, 0.300 and 31.3 %, 95.3 %, 0.266, respectively. For combined detection of CEA, CA199, CA242, CA724, the sensitivity, specificity and Youden Index were 76.8 %, 82.3 %, 01585. The levels of CEA, CA724 were closely related to lymph node status (both P 〈 0.05). The concentrations of CEA, CA199, CA242 were significantly related to vascular embolization, distant metastases and ascites (all P 〈 0.05). The patients of lump and catheter had significantly higher of AFP compared with patients of invasion and anabrosis (P 〈 0.05). In gastric cancer patients, the size of the primary tumors was closely related to the preoperative serum levels of CEA, AFP, CA724 (P 〈 0.05). During follow-up, there were 34 cases of death in 59 patients, and the median survival time were 18.1, 10.9 months for the patients with CEA negative and positive (P 〈 0.005). Conclusions Combing detection of CEA, CA199, CA242, CA72 can improve sensitivity of gastric cancer, and play an important role in forecasting the recurrence, metastasis, curing and prognosis evaluation. CEA is an important predictor of recurrence and prognosis of gastric cancer.
出处 《肿瘤研究与临床》 CAS 2014年第3期183-186,共4页 Cancer Research and Clinic
关键词 胃肿瘤 肿瘤标志物 预后评估 诊断 Stomach neoplasms Tumor markers Prognosis evaluation Diagnosis
  • 相关文献

参考文献6

二级参考文献71

  • 1谷玉兰,王熙才,金从国,陈艳,伍治平,黄焱坤.胃癌患者血清肿瘤标志物的特点及临床意义[J].肿瘤研究与临床,2005,17(5):329-331. 被引量:15
  • 2张青云.肿瘤标志物临床检测技术现状及发展趋势[J].中华检验医学杂志,2006,29(7):585-589. 被引量:29
  • 3季加孚,武爱文.进展期胃癌新辅助化疗的研究进展[J].中华胃肠外科杂志,2007,10(4):394-395. 被引量:58
  • 4Takahashi Y, Takeuchi T, Sakamoto J, et al. The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer, 2003, 6: 142-145.
  • 5Choi SR, Jang JS, Lee JH, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci, 2006, 51:2081-2086.
  • 6Goral V, Yesilbagdan H, Kaplan A, et al. Evaluation of CA 72-4 as a tumor marker in patients with gastric cancer. Hepatogastroenterology, 2007, 54:1272-1275.
  • 7Gupta G, Sharma R, Chattopadhyay TK, et al. Clinical significance of sperm protein 17 expression and immunogenicity in esophageal cancer. Int J Cancer, 2007, 120: 1739-1747.
  • 8Wilson MS, Nie W. Multiplex measurement of seven tumor markers using an electrochemical protein chip. Anal Chem, 2006, 78: 6476-6483.
  • 9Alaiya A, Mohanna MA, Linder S. Clinical cancer proteomics: Promises and pitfalls. Proteome Res, 2005, 4: 1213-1222.
  • 10Balachandra K, Laisupasin P, Dhepakson P, et al. Preliminary clinical evaluation of a protein chip for tumor marker serodiagnosis of various cancers. Asian Pac J Allergy Immunol, 2003, 21: 171-178.

共引文献143

同被引文献359

引证文献48

二级引证文献401

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部